Results 61 to 70 of about 174,614 (242)

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

open access: yes, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO‐01)

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Our aim was to compare the outcomes of preoperative chemotherapy with postoperative chemotherapy in patients with resectable colorectal liver metastases treated with CAPOX‐Bev. We demonstrated that both preoperative and postoperative CAPOX‐Bev were safely administered, and preoperative chemotherapy showed a numerically higher treatment compliance rate ...
Yuji Takakura   +15 more
wiley   +1 more source

BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature. [PDF]

open access: yes, 2019
BackgroundHereditary colon cancer is characterized by the inheritance of an abnormal gene mutation which predisposes to malignancy. Recent advances in genomic medicine have identified mutations in "novel" genes as conferring an increased risk of ...
Ali, Mir   +2 more
core  

Long‐Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p 
Takahito Sugase   +19 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda   +3 more
wiley   +1 more source

Enhancing anticancer cytotoxicity through bimodal drug delivery from ultrasmall Zr MOF nanoparticles [PDF]

open access: yes, 2018
Dual delivery of dichloroacetate and 5-fluorouracil from Zr MOFs into cancer cells is found to enhance in vitro cytotoxicity. Tuning particle size and, more significantly, surface chemistry, further improves cytotoxicity by promoting caveolae-mediated ...
Abánades Lázaro, Isabel   +2 more
core   +1 more source

Significance of Neoadjuvant S‐1‐Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Neoadjuvant chemotherapy (NAC) has been extensively developed for locally advanced gastric cancer (GC). In Asia, S‐1‐based regimens, such as docetaxel, oxaliplatin, and S‐1 (DOS) and S‐1 and oxaliplatin (SOX), are expected to become the standard of care.
Kota Kawabata   +9 more
wiley   +1 more source

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. [PDF]

open access: yes, 2014
A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584,
Gruber, Harry E   +11 more
core   +2 more sources

A Transcriptome‐Wide Mendelian Randomization Study in Isolated Human Immune Cells Highlights Risk Genes Involved in Viral Infections and Potential Drug Repurposing Opportunities for Schizophrenia

open access: yesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, EarlyView.
ABSTRACT Schizophrenia is a neurodevelopmental psychiatric disorder characterized by symptoms of psychosis, thought disorder, and flattened affect. Immune mechanisms are associated with schizophrenia, though the precise nature of this relationship (causal, correlated, consequential) and the mechanisms involved are not fully understood.
David Stacey   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy